CutisPharma announced the availability of Firvanq™ (vancomycin HCl) for oral solution to treat Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.
Firvanq, which was approved in January 2018, is replacing the Company’s FIRST Vancomycin Unit-of-Use Compounding Kit. The new ready-to-use oral liquid eliminates the need for compounding by a pharmacist.
Each Firvanq kit contains vancomycin HCl powder for oral solution, equivalent to 3.75g, 7.5g, or 15g vancomycin and grape-flavored diluent. Prior to oral administration, the supplied Firvanq powder must be reconstituted to produce the oral solution (25mg/mL or 50mg/mL strengths).
When not in use, reconstituted solutions of Firvanq should be refrigerated; reconstituted solutions should be discarded after 14 days, or if the solution appears hazy or contains particulates.
For more information call (800) 461-7449 or visit Firvanq.com.
This article originally appeared on MPR